MI-EATON
14.7.2020 23:39:14 CEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has been leveraging advanced Industry 4.0 technology to help its global operations safely navigate the ongoing COVID-19 crisis and continue to service its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714006047/en/
Eaton’s Vehicle Group envisions Industry 4.0 as both operational and informational technologies, enabling autonomous production systems that are connected, optimized, transparent, proactive, and agile. Supported by an integrated ecosystem, the technologies are composed of augmented reality, rapid application development, autonomous robots, digital simulation, and additive manufacturing.
“I’m proud of our Vehicle Group team and their ingenuity, especially during the COVID-19 pandemic,” said João Faria, president, Vehicle Group. “By leveraging augmented reality, we are able to continue to support our operations remotely and continue the development of new products, ensuring our customer deadlines are met despite the global challenges we are all facing.”
Here are examples of how the Vehicle Group is using Industry 4.0 technologies:
Displaying 3D images and connecting remotely to improve safety
To enable remote assistance and critical activities, Vehicle Group teams are using Microsoft’s HoloLens 2 augmented reality goggles that offer the capability to display 3D images in physical spaces and connect remotely. This remote assistance technology ensures that ongoing work can be performed while keeping everyone safe.
Enhancing training and expediting review processes through augmented reality
Augmented reality also assists with knowledge retention and ongoing training. For instance, the Vehicle Group identified an opportunity to use the technology to train operators and engineers on new equipment, which would have traditionally been conducted by instructors who travel to the various remote sites. Additionally, the technology has proven critical for recent customer reviews and approvals.
Analyzing data to reduce costs, improve quality and reduce lead times
Eaton’s Vehicle Group is interconnecting plant systems and machines to collect, analyze and report real-time information, which optimizes plant floor management and provides visibility to real-time production issues in order to address them right away. These efforts are designed to reduce lead times; maintenance, repair and operations (MRO), inventory, indirect-labor/direct-labor costs; as well as increase performance and improve quality.
Implementing robots to promote safe distancing and increase productivity
To optimize manufacturing flow and eliminate the need for forklifts and other human-operated transport machinery, the Vehicle Group is using autonomous automated guided vehicles (AGVs) or autonomous mobile robots (AMRs). In addition to improving the flow of materials throughout a manufacturing facility, AMRs and autonomous AGVs increase safety and allow for social distancing while also lowering costs.
COBOTs, which are robots intended to interact with humans in a shared space or to work safely in close proximity, are being used to safely handle complex and repetitive tasks. This results in improved consistency and accuracy during the manufacturing process.
Using digital simulation to improve production efficiency
Another way the Vehicle Group is increasing productivity is by using digital simulation applications to define which solution and/or combination of factors will result in the highest output. These applications can run several scenarios by changing parameters, such as the number of operators, work in process material, cycle times, operator standardized work and many others. The applications are being used to define new manufacturing cells and assembly lines or to redesign existing ones. In most cases, the Vehicle Group is seeing productivity increase from 10 to 30 percent via higher production output or reduced amount of investment needed.
Leveraging 3D printing tools internally to expedite processes
Additive manufacturing is leveraged to improve safety, quality and efficiency by designing and producing tools, poke-yokes and gauges internally on both polymer and metal materials. This allows fast reactions (shorter lead times), reduced purchase costs and highly customized solutions. For example, lead times can be reduced from weeks to days, while reducing costs from thousands to hundreds.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2019 revenues were $21.4 billion, and we sell products to customers in more than 175 countries. We have approximately 95,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714006047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
